Aligos Therapeutics (NASDAQ:ALGS) Rating Lowered to Sell at Wall Street Zen

Aligos Therapeutics (NASDAQ:ALGS) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Other research analysts have also issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Wednesday, January 21st. UBS Group initiated coverage on Aligos Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $35.00.

Aligos Therapeutics Trading Up 4.8%

Shares of ALGS stock opened at $6.98 on Friday. The firm has a market capitalization of $42.93 million, a P/E ratio of -0.81 and a beta of 2.67. Aligos Therapeutics has a 1 year low of $3.76 and a 1 year high of $13.69. The firm’s fifty day simple moving average is $7.88 and its 200 day simple moving average is $9.07.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Monday, March 9th. The company reported ($1.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.09) by $0.18. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 25.01%. The firm had revenue of $0.17 million during the quarter. Equities research analysts anticipate that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. NorthCrest Asset Manangement LLC acquired a new stake in shares of Aligos Therapeutics during the third quarter worth $98,000. Susquehanna International Group LLP bought a new stake in Aligos Therapeutics in the 3rd quarter valued at approximately $99,000. HRT Financial LP acquired a new position in Aligos Therapeutics during the 4th quarter worth approximately $106,000. DRW Securities LLC acquired a new position in Aligos Therapeutics during the 4th quarter worth approximately $111,000. Finally, XTX Topco Ltd bought a new stake in Aligos Therapeutics during the 2nd quarter worth about $100,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.